Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Severe Combined Immunodeficiency: early-phase trial registry
2 of 7 indexed Severe Combined Immunodeficiency trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Severe Combined Immunodeficiency: 7 US clinical trials tracked, 2 recruiting.
Severe Combined Immunodeficiency is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 2 of these trials.
Enrollment posture brief
Registry condition severe-combined-immunodeficiency
OPEN 2 | RECR 29% | LATE 0 | EARLY 4 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)
Severe Combined Immunodeficiency lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Severe Combined Immunodeficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Severe Combined Immunodeficiency is recruiting below its size-band peers.
2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Severe Combined Immunodeficiency research.
University of California, San Francisco accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Severe Combined Immunodeficiency trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Severe Combined Immunodeficiency splits between interventional and observational designs.
4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Genetic Basis of Immunodeficiency
National Heart, Lung, and Blood Institute (NHLBI)
NCT00055172
Autologous Gene Therapy for Artemis-Deficient SCID
University of California, San Francisco
NCT03538899
Immune Disorder HSCT Protocol
Washington University School of Medicine
NCT01821781
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
St. Jude Children's Research Hospital
NCT03597594
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
University of California, San Francisco
NCT00845416
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
National Human Genome Research Institute (NHGRI)
NCT00006335
IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
Emory University
NCT00228852
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Severe Combined Immunodeficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Severe Combined Immunodeficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Severe Combined Immunodeficiency page
7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Severe Combined Immunodeficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of California, San Francisco sponsors the most Severe Combined Immunodeficiency trials on record, review their full trial history before evaluating a specific study. See University of California, San Francisco's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Severe Combined Immunodeficiency condition card totals 7 registered trials; most-linked intervention Busulfan; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.